Detalles de la búsqueda
1.
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
Int J Geriatr Psychiatry
; 37(10)2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36168659
2.
Regression patterns of central serous chorioretinopathy using en face optical coherence tomography.
Graefes Arch Clin Exp Ophthalmol
; 260(8): 2475-2481, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35357548
3.
Assessment of sigma-1 receptor occupancy in mice with non-radiolabelled FTC-146 as a tracer.
J Recept Signal Transduct Res
; 38(4): 290-298, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29912606
4.
Effects of hydroxychloroquine therapy on choroidal volume and choroidal vascularity index.
Eye (Lond)
; 38(3): 620-624, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37770532
5.
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
Biomolecules
; 13(2)2023 02 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36830678
6.
Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling.
Eur J Pharmacol
; 947: 175625, 2023 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36997046
7.
A selective and accurate liquid chromatography-tandem mass spectrometry method for the quantitation of the novel 5-HT4 receptor partial agonist SUVN-D4010 (Usmarapride) in human plasma and urine.
J Pharm Biomed Anal
; 211: 114617, 2022 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35124447
8.
Treatment of chronic plaque psoriasis with herbal Unani formulations: A randomized control trial of efficacy and safety.
J Ethnopharmacol
; 296: 115456, 2022 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35724745
9.
Evaluating the safety and efficacy of a polyherbal Unani formulation in dyslipidaemia-a prospective randomized controlled trial.
J Ethnopharmacol
; 289: 115036, 2022 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35114340
10.
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4ß2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
Clin Drug Investig
; 42(9): 747-762, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35963959
11.
Ropanicant (SUVN-911), an α4ß2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
Psychopharmacology (Berl)
; 239(7): 2215-2232, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35298691
12.
1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition.
ChemMedChem
; 17(3): e202100583, 2022 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761873
13.
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
Clin Drug Investig
; 41(5): 469-482, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33788154
14.
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.
J Med Chem
; 64(15): 10641-10665, 2021 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34251799
15.
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
Clin Drug Investig
; 40(7): 603-615, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32399853
16.
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy.
Eur J Pharm Sci
; 152: 105425, 2020 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32534194
17.
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4ß2 Receptor Antagonist for the Treatment of Depression.
J Med Chem
; 63(6): 2833-2853, 2020 03 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32026697
18.
LC-MS/MS method for quantification of 3,4-dihydroxyphenylglycol, a norepinephrine metabolite in plasma and brain regions.
Bioanalysis
; 11(10): 971-986, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31218903
19.
Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity.
J Med Chem
; 62(3): 1203-1217, 2019 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30629436
20.
Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists.
J Med Chem
; 61(11): 4993-5008, 2018 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29763304